Andreas Thorstenson1,2, Oskar Hagberg3, Börje Ljungberg4, Fredrik Liedberg5, Georg Jancke6, Sten Holmäng7, Per-Uno Malmström8, Abolfazl Hosseini1, Staffan Jahnson6. 1. a Department of Molecular Medicine and Surgery, Section of Urology , Karolinska Institute , Stockholm , Sweden ; 2. b Department of Surgery, Section of Urology , Capio St Göran's Hospital , Stockholm , Sweden ; 3. c Regional Cancer Center, Lund University , Lund , Sweden ; 4. d Department of Surgical and Perioperative Sciences, Urology and Andrology , Umeå University , Umeå , Sweden ; 5. e Department of Urology , SUS, Lund University , Malmö , Sweden ; 6. f Department of Urology , University Hospital, Linköping University , Linköping , Sweden ; 7. g Department of Urology , Sahlgrenska University Hospital , Göteborg , Sweden ; 8. h Department of Urology , Uppsala University Hospital , Uppsala , Sweden.
Abstract
OBJECTIVE: The aim of this investigation was to describe tumour characteristics, treatments and survival in patients with urinary bladder cancer (UBC) in a national population-based cohort, with special reference to gender-related differences. MATERIAL AND METHODS: All primary UBC patients with urothelial pathology reported to the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) from 1997 to 2011 were included in the study. Groups were compared regarding tumour, node, metastasis classification, primary treatment and survival. RESULTS: In total, 30,310 patients (74.9% male, 25.1% female) with UBC were analysed. A larger proportion of women than men had stage T2-T4 (p < 0.001), and women also had more G1 tumours (p < 0.001). However, compared to women, a larger proportion of men with carcinoma in situ or T1G3 received intravesical treatment with bacillus Calmette-Guérin or intravesical chemotherapy, and a larger proportion of men with stage T2-T4 underwent radical cystectomy (38% men vs 33% women, p < 0.0001). The cancer-specific survival at 5 years was 77% for men and 72% for women (p < 0.001), and the relative survival at 5 years was 72% for men and 69% for women (p < 0.001). CONCLUSIONS: In this population-based cohort comprising virtually all patients diagnosed with UBC in Sweden between 1997 and 2011, female gender was associated with inferior cancer-specific and relative survival. Although women had a higher rate of aggressive tumours, a smaller proportion of women than men received optimal treatment.
OBJECTIVE: The aim of this investigation was to describe tumour characteristics, treatments and survival in patients with urinary bladder cancer (UBC) in a national population-based cohort, with special reference to gender-related differences. MATERIAL AND METHODS: All primary UBC patients with urothelial pathology reported to the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) from 1997 to 2011 were included in the study. Groups were compared regarding tumour, node, metastasis classification, primary treatment and survival. RESULTS: In total, 30,310 patients (74.9% male, 25.1% female) with UBC were analysed. A larger proportion of women than men had stage T2-T4 (p < 0.001), and women also had more G1 tumours (p < 0.001). However, compared to women, a larger proportion of men with carcinoma in situ or T1G3 received intravesical treatment with bacillus Calmette-Guérin or intravesical chemotherapy, and a larger proportion of men with stage T2-T4 underwent radical cystectomy (38% men vs 33% women, p < 0.0001). The cancer-specific survival at 5 years was 77% for men and 72% for women (p < 0.001), and the relative survival at 5 years was 72% for men and 69% for women (p < 0.001). CONCLUSIONS: In this population-based cohort comprising virtually all patients diagnosed with UBC in Sweden between 1997 and 2011, female gender was associated with inferior cancer-specific and relative survival. Although women had a higher rate of aggressive tumours, a smaller proportion of women than men received optimal treatment.
Authors: Carolyn D Hurst; Olivia Alder; Fiona M Platt; Alastair Droop; Lucy F Stead; Julie E Burns; George J Burghel; Sunjay Jain; Leszek J Klimczak; Helen Lindsay; Jo-An Roulson; Claire F Taylor; Helene Thygesen; Angus J Cameron; Anne J Ridley; Helen R Mott; Dmitry A Gordenin; Margaret A Knowles Journal: Cancer Cell Date: 2017-11-13 Impact factor: 31.743
Authors: Nathan Littlejohn; Joshua A Cohn; Casey G Kowalik; Melissa R Kaufman; Roger R Dmochowski; W Stuart Reynolds Journal: Curr Urol Rep Date: 2017-01 Impact factor: 3.092
Authors: Emanuele Zaffuto; Marco Bandini; Stéphanie Gazdovich; Anne-Sophie Valiquette; Sami-Ramzi Leyh-Bannurah; Zhe Tian; Paolo Dell'Oglio; Markus Graefen; Marco Moschini; Andrea Necchi; Shahrokh F Shariat; Alberto Briganti; Francesco Montorsi; Pierre I Karakiewicz Journal: World J Urol Date: 2018-04-27 Impact factor: 4.226
Authors: Ming Ping Wu; Hao Lun Luo; Shih Feng Weng; Chung-Han Ho; Michael B Chancellor; Yao Chi Chuang Journal: Biomed Res Int Date: 2018-06-28 Impact factor: 3.411